Download presentation
Presentation is loading. Please wait.
Published byPreston Snow Modified over 9 years ago
1
Signaling Pathways Produced By Combining DsRNA with Paclitaxal to treat Ovarian Cancer Switu Patel
2
Ovarian Cancer Fifth in, malignant deaths of US women Cause unknown Common Therapy: surgery + chemotherapy
3
Dual treatments In Van et al. they combined Double stranded RNA (DsRNA) with therapeutic agents like paclitaxel and carboplatin to get a significant decrease in cell viability DsRNA is known to stop the immunosuppression signals caused by ovarian tumor cells and activate four innate immune receptors
4
Cell response to dsRNA When stimulated within a cell, it activates four receptors.
5
Cell response to dsRNA DsRNA activates Protein Kinase and gives it a pro-apoptotic or cell killing response
6
Cell response to dsRNA Which then phosphorylates EIF2S which stops translation
7
Cell response to dsRNA Apoptosis PKR also activates FADD which further activates caspase 8
8
Cell response to dsRNA Apoptosis Other pathways that influence apoptosis
9
Individual vs. Combined treatments
11
Proposal question What essential pathways related to apoptosis are activated by dsRNA + paclitaxel? ◦ These pathways will serve as biomarkers for individual patients
12
Experiment Apoptotic PCR Array For: ◦ Untreated ◦ Treated: dsRNA, paclitaxel, dsRNA + paclitaxel
14
Hypothetical Results Caspase 3
15
Results We expect that the samples treated with combined therapeutic agents will have a higher levels of apoptotic pathway molecules or lower CT values, than the individual treated samples. However, it may cause down regulation of anti-apoptotic proteins or cause up regulation of pro-apoptotic or cell death proteins.
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.